UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section 13~~Report ~~or 15~~(d)Date of earliest event reported): June 6, 2007

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 23, 2007

STRATAGENE CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware	000-50786	33-0683641
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

11011 North Torrey Pines Road, La Jolla, California		92037
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 373-6300

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~This Current~~o Soliciting ~~Report~~material onpursuant ~~Form~~to 8Rule 14a-K12 isunder ~~filed~~the byExchange ~~Stratagene~~Act ~~Corporation, a Delaware corporation~~ (~~“Stratagene”), in~~17 ~~connection with the matters described herein~~CFR 240.14a-12)

~~Item~~o Pre-commencement communications ~~8.01.~~pursuant ~~Other~~to ~~Events~~Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Ono Pre-commencement communications ~~May~~pursuant 23, 2007, Stratagene received notice of a Writ of Summons (“Writ #1”) filed by Applera Corporation (“Applera”) against Stratagene and certain of its subsidiaries (collectively, the “Company”) in the District of The Hague in the Netherlands, to ~~appear at such court for a preliminary injunction hearing on Wednesday, July,~~ Rule 13e-4~~, 2007. On May 25, 2007, Stratagene received notice of a Writ of Summons~~ (~~“Writ #2”, and together with Writ #1, the “Writs”~~c) ~~filed~~under ~~by Applera against~~ the ~~Company~~Exchange inAct ~~the~~(17 ~~Tribunal de Grande Instance of Paris, to appoint a barrister from the Paris bar by August 9, 2007~~CFR 240. The Writs allege, among other things, that the Company has infringed EU patent no. 0 872 562 B1. The Stratagene products alleged to infringe such patent are the Mx3000P, Mx3005P and Mx4000P instruments and certain related reagents. Among other things set forth in the Writs, Applera seeks a preliminary injunction preventing the Company from engaging in allegedly infringing activity in The Netherlands, France and certain other European nations. The Company believes the claims asserted in the Writs are without merit and intends to vigorously defend against these actions.13e-4(c))

2Item 5.01. Changes in Control of Registrant.

~~SIGNATURES~~On June 6, 2007, Stratagene Corporation, a Delaware corporation (the “Company”), held its Special Meeting of Stockholders (the “Special Meeting”) in La Jolla, California, at which approximately 79.8% of the Company’s stockholders adopted the Agreement and Plan of Merger, dated as of April 5, 2007 (the “Merger Agreement”), by and among Agilent Technologies, Inc. (“Agilent”), Jackson Acquisition Corp., a wholly-owned subsidiary of Agilent (“Merger Sub”), and the Company. Also on June 6, 2007, following the adoption of the Merger Agreement by the Company’s stockholders at the Special Meeting, the Company completed the merger of Merger Sub with and into the Company (the “Merger”) pursuant to the terms of the Merger Agreement. As a result of the Merger, the Company became a wholly-owned subsidiary of Agilent.

~~Pursuant~~Upon consummation of the Merger and pursuant to the terms ~~requirements~~of the Merger Agreement, each share of Company common stock that was issued and outstanding immediately prior to the ~~Securities~~Merger ~~Exchange~~was ~~Act~~converted into and represents the right to receive an amount of ~~1934~~cash, without interest, equal to $10.94. In addition, each vested option to purchase Company common stock with an exercise price per share that was less than $10.94 and that was issued and outstanding immediately prior to the ~~registrant~~Merger ~~has~~was ~~duly~~converted into and represents the right to ~~caused~~receive ~~this~~an ~~report~~amount of cash, without interest, equal to bethe ~~signed~~product onof ~~its~~(i) ~~behalf~~the number of shares of Company common stock subject to such vested Company option multiplied by (ii) the ~~undersigned~~sum ~~hereunto~~of ~~duly~~$10.94 minus the exercise price per share of ~~authorized~~Company common stock subject to such vested Company option. Vested options to purchase Company common stock with an exercise price per share equal to or greater than $10.94, and unvested options to purchase Company common stock, that were, in each case, issued and outstanding immediately prior to Merger, were cancelled and extinguished without any payment or other consideration therefor or the issuance of any securities in exchange or substitution therefor.

Date: May 29, 2007	STRATAGENE CORPORATION
	By:	/s/ STEVE MARTIN
		Name:	Steve Martin
		Title:	Vice President and Chief Financial Officer

The Company’s common stock ceased trading on The Nasdaq Global Market at the close of business on June 6, 2007. In connection with the Merger, the Company filed a Form 15 Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934, as amended, on June 7, 2007 to terminate the registration of the Company’s common stock.

3The information set forth in Item 1.01 to the Company’s Current Report on Form 8-K filed on April 11, 2007 and a copy of the Merger Agreement, which was attached as Exhibit 2.1 thereto, are incorporated herein by reference as though fully set forth herein. The foregoing summary description of the Merger Agreement and the transactions contemplated thereby is not intended to be complete and is qualified in its entirety by the complete text of the Merger Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 7, 2007	STRATAGENE CORPORATION

	By:	/s/ Marie Oh Huber
		Name:	Marie Oh Huber
		Title:	Chief Financial Officer

Filing Compare · STRATAGENE CORP